Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Meningioma 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 27Specimen Handling 21apalutamide 18Androgen Antagonists 16Prednisone 15Abiraterone Acetate 15Radiosurgery 13abiraterone 11Radiotherapy 10Docetaxel 10Biopsy 9darolutamide 8Pluvicto 8Nivolumab 8niraparib 6cabazitaxel 6Surveys and Questionnaires 6Radiation 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6gallium 68 PSMA-11 5bicalutamide 5Radiotherapy, Intensity-Modulated 5Lutetium 5Gonadotropin-Releasing Hormone 5radium Ra 223 dichloride 4pembrolizumab 4luprolide acetate gel depot 4cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × gallium Ga 68 dotatate × 30 days × Clear all
NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡